Publisher’s Note
Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group
J Clin Oncol Ajani et al. 25:3205
The August 1, 2007, article by Ajani et al entitled, “Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Cancer Adenocarcinoma: The V-325 Study Group” (J Clin Oncol 25:3205–3209, 2007) was published online July 30, 2007 with errors.
The title should not have included the word “Cancer,” and should have read:
“Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group”
In Table 2, the last footnote was given as:
“§Defined as the first opioid intake for grade > 3 cancer pain or death if death was the reason for treatment discontinuation; percent of assessable patients with an event is shown in parenthesis.”
While it should have read:
“§Defined as the first opioid intake for grade > 3 cancer pain or death if death was the reason for treatment discontinuation.”
In the Author Contributions section, all authors should have been acknowledged for “Collection and assembly of data.”
All corrections have been made as of November 16, 2007.
|
